(Q51304729)

3 April 2018

title

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models. (English)

1 reference

3 April 2018

1 reference

Mi-Kyung Kim

1

1 reference

3 April 2018

Yu Na Chae

2

1 reference

3 April 2018

Gook-Jun Ahn

3

1 reference

3 April 2018

Chang Yell Shin

4

1 reference

3 April 2018

Song-Hyen Choi

5

1 reference

3 April 2018

Eun Kyoung Yang

6

1 reference

3 April 2018

Yong Sung Sohn

7

1 reference

3 April 2018

Moon-Ho Son

8

1 reference

3 April 2018

publication date

24 November 2016

1 reference

3 April 2018

Archives of Pharmacal Research

published in

1 reference

3 April 2018

volume

40

1 reference

3 April 2018

issue

2

1 reference

3 April 2018

page(s)

268-281

1 reference

3 April 2018

https://scigraph.springernature.com/pub.10.1007/s12272-016-0864-z

exact match

0 references

cites work

Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Accretion of visceral fat and hepatic insulin resistance in pregnant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Effects of exercise training on subcutaneous and visceral adipose tissue in normal- and high-fat diet-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Non-alcoholic steatohepatitis in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Assessment of diet-induced obese rats as an obesity model by comparative functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

A fat-enriched, glucose-enriched diet markedly attenuates adiponectin mRNA levels in rat epididymal adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Long-term AICAR administration and exercise prevents diabetes in ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Nonalcoholic fatty liver disease: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Dissociating fatty liver and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

G protein-coupled receptors and the regulation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0864-Z

10.1007/S12272-016-0864-Z

21 January 2018

Identifiers

DOI

1 reference

3 April 2018

1 reference

3 April 2018